Ideally seeking immunological targets or antibodies to be produced with LFB's high ADCC MAb's platform which creates and develop highly cytotoxic MAb's or to be produced in the milk of transgenic animals.

LFB has developed a proprietary platform to create and develop highly cytotoxic MAb’s due to specific glycosylation patterns. LFB is also engaged in a strategic alliance with GTC to produce recombinant proteins and MAbs in the milk of transgenic animals.

LFB is also seeking for recombinant proteins to be as well produced in the milk of transgenic animals. LFB is open to licensing monoclonal antibodies or recombinant proteins produced with standard technologies addressing severe diseases.

LFB is a fully integrated biological company and has also interest in being associated to the clinical development of MAbs and recombinant proteins expressed in classical expression systems and addressing severe and even orphan pathologies.

 

LFB is seeking partners/companies which are looking for a strategic partnership based on the development of a portfolio of highly active MAbs with post-translational modification of the glycosylation pattern or on the development of a portfolio of recombinant proteins.